Drug discovery: How melanomas bypass new therapy Journal Article

  

Authors:	Solit, D.; Sawyers, C. L.
Article Title:	Drug discovery: How melanomas bypass new therapy
Keywords:	protein expression; treatment response; leukemia; gene mutation; mutation; proto-oncogene proteins; clinical trial; erlotinib; drug efficacy; note; imatinib; melanoma; neoplasm recurrence, local; map kinase signaling system; lung cancer; enzyme activation; drug resistance, neoplasm; dasatinib; chronic myeloid leukemia; cancer therapy; cancer resistance; protein kinase inhibitors; cancer inhibition; oncogene; gene expression regulation, neoplastic; sulfonamides; tumor cell; extracellular signal-regulated map kinases; adenosine triphosphate; nilotinib; indoles; b raf kinase; mitogen-activated protein kinase kinases; drug binding; proto-oncogene proteins b-raf; plx 4032; proto-oncogene proteins c-raf; gastrointestinal tumor; map kinase kinase kinases; mitogen activated protein kinase 11
Journal Title:	Nature
Volume:	468
Issue:	7326
ISSN:	0028-0836
Publisher:	Nature Publishing Group
Date Published:	2010-12-16
Start Page:	902
End Page:	903
Language:	English
DOI:	10.1038/468902a
PUBMED:	21164474
PROVIDER:	scopus
DOI/URL:	http://www.scopus.com/inward/record.url?eid=2-s2.0-78650373172&partnerID=40&md5=a8db71965d209f98a8ba13941dbed495
Notes:	--- - "Cited By (since 1996): 1" - "Export Date: 20 April 2011" - "CODEN: NATUA" - "Source: Scopus"

https://synapse.mskcc.org/synapse/works/has_related_data_chk/5140